Pulmonary Arterial Hypertension

Prognostic Value of 6MWT in Pulmonary Arterial Hypertension

Prognostic Value of 6MWT in Pulmonary Arterial Hypertension

By

The 6-minute walk test had prognostic value with respect to mortality in a population of patients with pulmonary arterial hypertension.

Pulmonary Arterial Hypertension: Improving Survival Rates

Pulmonary Arterial Hypertension: Improving Survival Rates

By

Brain natriuretic peptide levels may accurately predict 5-year survival rates in patients with pulmonary arterial hypertension.

REVEAL Risk Score for Long-Term Outcomes in PAH

REVEAL Risk Score for Long-Term Outcomes in PAH

By

The REVEAL risk score gives significant predictive value for long-term survival and changes in mortality risk in patients with PAH.

PAH: Implantable Treprostinil Delivery System Is Promising

PAH: Implantable Treprostinil Delivery System Is Promising

By

A fully implantable programmable intravascular delivery system using treprostinil was found to be highly stable in patients with PAH.

Pulmonary Arterial Hypertension Survival May Be Linked to Kidney Function

Pulmonary Arterial Hypertension Survival May Be Linked to Kidney Function

By

A study evaluated whether changes in estimated glomerular filtration rate were predictive of mortality in patients with pulmonary arterial hypertension.

Clinical Challenge: 40-Year-Old Woman With Worsening Dyspnea on Exertion

Clinical Challenge: 40-Year-Old Woman With Worsening Dyspnea on Exertion

By

A 40-year-old woman presents with worsening shortness of breath after being treated with long-acting nifedipine for 2 years.

Improved Hemodynamics in CTEPH With Balloon Pulmonary Angioplasty

Improved Hemodynamics in CTEPH With Balloon Pulmonary Angioplasty

By

Hemodynamics may improve in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty with complication rates comparable to pulmonary endarterectomy.

Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response

Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response

By

Using biomarkers in pulmonary arterial hypertension may be a less invasive strategy for assessing response to treatment.

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Definitions and Treatments

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Definitions and Treatments

By

Pulmonary arterial hypertension is becoming a major cause of death in patients with systemic sclerosis.

Idiopathic PAH vs Scleroderma-Associated PAH: Pulmonary Function and Hemodynamic Differences

Idiopathic PAH vs Scleroderma-Associated PAH: Pulmonary Function and Hemodynamic Differences

By

Results show statistically significant differences between SSc-PAH groups and iPAH groups for variables including age, sex, FVC capacity, total lung capacity, and FEV1, among others.

Impaired Cerebral Pressure-Flow Relationship in PAH

Impaired Cerebral Pressure-Flow Relationship in PAH

By

Patients with pulmonary arterial hypertension have reduced cerebrovascular reactivity to CO2.

Pulmonary HTN Linked to Increased Mortality During Cardiac Catheterization

Pulmonary HTN Linked to Increased Mortality During Cardiac Catheterization

Borderline PH was linked to increased mortality after adjustment for 34 variables.

No Associations Exist Between 6MWD and Maximum Oxygen Uptake in Pulmonary Arterial Hypertension

No Associations Exist Between 6MWD and Maximum Oxygen Uptake in Pulmonary Arterial Hypertension

By

Results indicate that further study of the relationship between the 6-minute walk distance test and functional capacity in PAH is necessary.

Association Between Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia

Association Between Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia

By

A study sought to describe the occurrence of different types of pulmonary hypertension in hereditary hemorrhagic telangiectasia.

Examining Anxiety, Depression Rates in CTEPH, PAH

Examining Anxiety, Depression Rates in CTEPH, PAH

By

Depression, anxiety, and reduced healthcare-related quality of life are common in patients with either pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Clinical Case: Patient With COPD and Worsening Dyspnea on Exertion

Clinical Case: Patient With COPD and Worsening Dyspnea on Exertion

By

A 65-year-old man with COPD presents with worsening exertional dyspnea.

Characteristics and Outcomes of Methamphetamine-Associated Pulmonary Arterial Hypertension

Characteristics and Outcomes of Methamphetamine-Associated Pulmonary Arterial Hypertension

By

Methamphetamine-associated pulmonary arterial hypertension has a higher risk for clinical worsening compared with idiopathic pulmonary arterial hypertension.

Pulmonary Veno-Occlusive Disease Affects Survival in PAH/Systemic Sclerosis

Pulmonary Veno-Occlusive Disease Affects Survival in PAH/Systemic Sclerosis

By

Having at least 2 features of pulmonary veno-occlusive disease demonstrated a trend toward worse survival in patients with pulmonary arterial hypertension and systemic sclerosis.

Pulmonary Arterial Hypertension: Future Treatment May Depend on Race and Ethnicity

Pulmonary Arterial Hypertension: Future Treatment May Depend on Race and Ethnicity

By

Pulmonary arterial hypertension tends to vary in presentation in patients of different races and ethnicities.

Right Ventricular Morphology Predictive of Pulmonary Hypertension Type

Right Ventricular Morphology Predictive of Pulmonary Hypertension Type

By

Differences in right ventricular morphology may predict the hemodynamic nature of pulmonary hypertension.

Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension

Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension

Pulmonary endarterectomy is an effective and durable treatment for chronic thromboembolic pulmonary hypertension.

Managing Pulmonary Hypertension in Preterm Neonates: Updates in an Emerging Field

Managing Pulmonary Hypertension in Preterm Neonates: Updates in an Emerging Field

By

Prenatal factors such as intrauterine growth retardation, infection, and placental inflammation can affect lung development in neonates.

Pediatric Pulmonary Arterial Hypertension Drug Approved by FDA

Pediatric Pulmonary Arterial Hypertension Drug Approved by FDA

By

The first FDA-approved drug for pediatric pulmonary arterial hypertension will be available in 32 mg tablets for oral suspension.

Safety, Efficacy of Treprostinil Delivery System for PAH Examined

Safety, Efficacy of Treprostinil Delivery System for PAH Examined

By

Researchers were able to successfully use a fully implantable delivery system for treprostinil for adult patients with pulmonary arterial hypertension.

ACR Imaging Criteria for Suspected Pulmonary Hypertension

ACR Imaging Criteria for Suspected Pulmonary Hypertension

By

New criteria by the American College of Radiology detail appropriateness of various imaging techniques for suspected pulmonary hypertension.

Predicting Survival in IPF With CT-Measured Pulmonary Artery: Aorta Ratio

Predicting Survival in IPF With CT-Measured Pulmonary Artery: Aorta Ratio

By

Computed tomography-derived pulmonary artery-to-aorta ratio can predict pulmonary artery pressure and survival in patients with idiopathic pulmonary fibrosis.

Biomarkers of PAH Risk in Patients With SLE

Biomarkers of PAH Risk in Patients With SLE

By

Meta-analysis supports anti-RNP and anti-Sm antibodies as serological biomarkers of PAH risk in patients with SLE.

MRIs Can Predict Outcomes in Pulmonary Arterial Hypertension

MRIs Can Predict Outcomes in Pulmonary Arterial Hypertension

MRI measures can predict outcomes in pulmonary arterial hypertension.

Pulmonary Arterial Hypertension: Expert Interview

Pulmonary Arterial Hypertension: Expert Interview

By

Pulmonary and genetics experts James E. Loyd, MD, and Wendy Chung, MD, PhD, offer insight into the role of genetics in pulmonary arterial hypertension.

Safety and Efficacy of Combination Treatment for CTD-PAH

Safety and Efficacy of Combination Treatment for CTD-PAH

By

Combination therapy with ambrisentan and tadalafil may improve response in patients with connective tissue disease-associated pulmonary arterial hypertension.

Sign Up for Free e-newsletters